Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for NRIX

Stock NameNurix Therapeutics Inc
TickerNRIX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS67080M1036

Show aggregate NRIX holdings

News associated with NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.87 Consensus Target Price from Brokerages
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target […] - 2025-08-27 02:54:56
18,716 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by XTX Topco Ltd
XTX Topco Ltd purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,716 shares of the company’s stock, valued at approximately $222,000. Other institutional investors and hedge funds have also […] - 2025-08-13 04:26:46
TD Asset Management Inc Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
TD Asset Management Inc increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,420 shares of the company’s stock after purchasing an additional 3,186 […] - 2025-08-05 04:34:52
HC Wainwright Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $34.00
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its target price cut by equities research analysts at HC Wainwright from $36.00 to $34.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 179.84% from the stock’s previous […] - 2025-07-16 04:26:52
Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.18
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month […] - 2025-07-08 03:10:44
Nurix: European Medicines Agency Grants Orphan Drug Designation To Bexobrutideg
(RTTNews) - Nurix Therapeutics (NRIX) announced that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Brutons tyrosine kinase whic - 2025-07-07 08:41:27
Sumitomo Mitsui Trust Group Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Sumitomo Mitsui Trust Group Inc. reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 4.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755,970 shares of the company’s stock after selling 33,252 shares during the […] - 2025-07-04 05:13:03
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.18
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month target price […] - 2025-06-13 02:32:51
The Math Shows ESML Can Go To $48
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:20:56
ProShare Advisors LLC Acquires 7,261 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 45.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,132 shares of the company’s stock after buying an additional 7,261 shares during the period. […] - 2025-05-28 05:09:01
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.44
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price […] - 2025-05-19 02:32:50
First Trust Advisors LP Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
First Trust Advisors LP bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 135,903 shares of the company’s stock, valued at approximately $2,560,000. First Trust Advisors LP owned approximately […] - 2025-05-05 06:24:57
Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Invesco Ltd. lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,980 shares of the company’s stock after selling 361,360 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-02 05:06:53
Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Norges Bank acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 318,800 shares of the company’s stock, valued at approximately $6,006,000. Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC purchased a new stake in […] - 2025-04-10 05:34:49
Vanguard Group Inc. Has $81.87 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.3% during the 4th quarter, HoldingsChannel reports. The fund owned 4,345,266 shares of the company’s stock after acquiring an additional 333,452 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Nurix Therapeutics worth $81,865,000 as of its most […] - 2025-04-10 04:44:59
Peek Under The Hood: DFAC Has 28% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price […] - 2025-03-27 04:38:49
US Bancorp DE Has $27,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
US Bancorp DE raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 144.7% in the 4th quarter, HoldingsChannel reports. The fund owned 1,424 shares of the company’s stock after acquiring an additional 842 shares during the period. US Bancorp DE’s holdings in Nurix Therapeutics were worth $27,000 at the end of the […] - 2025-03-20 06:28:53
Bank of New York Mellon Corp Purchases 15,639 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Bank of New York Mellon Corp lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,905 shares of the company’s stock after buying an additional 15,639 shares during the […] - 2025-03-20 06:28:53
Leerink Partners Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX)
Leerink Partners began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report published on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $16.00 price target on the stock. Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on […] - 2025-03-18 04:30:53
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective […] - 2025-03-05 04:53:07
Rhumbline Advisers Acquires 12,315 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Rhumbline Advisers raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 13.5% during the fourth quarter, Holdings Channel reports. The firm owned 103,233 shares of the company’s stock after buying an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Nurix Therapeutics were worth $1,945,000 at the end of […] - 2025-03-04 06:10:55
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 8.55% from […] - 2025-02-05 04:44:53

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NRIX holdings

DateNumber of NRIX Shares HeldBase Market Value of NRIX SharesLocal Market Value of NRIX SharesChange in NRIX Shares HeldChange in NRIX Base ValueCurrent Price per NRIX Share HeldPrevious Price per NRIX Share Held
2025-11-13 (Thursday)21,985USD 273,274USD 273,274
2025-11-12 (Wednesday)21,985NRIX holding decreased by -72USD 267,557NRIX holding decreased by -16096USD 267,557-72USD -16,096 USD 12.17 USD 12.86
2025-11-11 (Tuesday)22,057USD 283,653NRIX holding increased by 13455USD 283,6530USD 13,455 USD 12.86 USD 12.25
2025-11-10 (Monday)22,057USD 270,198NRIX holding decreased by -1324USD 270,1980USD -1,324 USD 12.25 USD 12.31
2025-11-07 (Friday)22,057USD 271,522NRIX holding decreased by -4632USD 271,5220USD -4,632 USD 12.31 USD 12.52
2025-11-06 (Thursday)22,057NRIX holding decreased by -72USD 276,154NRIX holding increased by 537USD 276,154-72USD 537 USD 12.52 USD 12.455
2025-11-05 (Wednesday)22,129NRIX holding decreased by -720USD 275,617NRIX holding decreased by -4512USD 275,617-720USD -4,512 USD 12.455 USD 12.26
2025-11-04 (Tuesday)22,849NRIX holding decreased by -144USD 280,129NRIX holding decreased by -10043USD 280,129-144USD -10,043 USD 12.26 USD 12.62
2025-11-03 (Monday)22,993NRIX holding decreased by -144USD 290,172NRIX holding decreased by -9221USD 290,172-144USD -9,221 USD 12.62 USD 12.94
2025-10-31 (Friday)23,137USD 299,393NRIX holding increased by 3702USD 299,3930USD 3,702 USD 12.94 USD 12.78
2025-10-30 (Thursday)23,137USD 295,691NRIX holding increased by 24988USD 295,6910USD 24,988 USD 12.78 USD 11.7
2025-10-29 (Wednesday)23,137USD 270,703NRIX holding decreased by -4627USD 270,7030USD -4,627 USD 11.7 USD 11.9
2025-10-28 (Tuesday)23,137NRIX holding increased by 216USD 275,330NRIX holding increased by 736USD 275,330216USD 736 USD 11.9 USD 11.98
2025-10-27 (Monday)22,921USD 274,594NRIX holding increased by 20400USD 274,5940USD 20,400 USD 11.98 USD 11.09
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NRIX by Blackrock for IE00B3VWM098

Show aggregate share trades of NRIX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-7213.15012.150 12.250USD -882 14.44 Profit of 157 on sale
2025-11-06SELL-7212.88012.300 12.358USD -890 14.48 Profit of 153 on sale
2025-11-05SELL-72013.03011.980 12.085USD -8,701 14.49 Profit of 1,730 on sale
2025-11-04SELL-14412.53012.160 12.197USD -1,756 14.50 Profit of 332 on sale
2025-11-03SELL-14413.18012.280 12.370USD -1,781 14.51 Profit of 308 on sale
2025-10-28BUY21611.90012.450 12.395USD 2,677 14.56
2025-10-24SELL-7211.09011.220 11.207USD -807 14.59 Profit of 244 on sale
2025-10-15BUY43210.35010.430 10.422USD 4,502 14.76
2025-10-02BUY729.0809.690 9.629USD 693 14.82
2025-09-30BUY1449.2409.410 9.393USD 1,353 14.89
2025-08-21SELL-729.6509.695 9.690USD -698 15.07 Profit of 387 on sale
2025-07-31BUY21611.26011.670 11.629USD 2,512 15.12
2025-06-30SELL-14411.39011.965 11.908USD -1,715 15.52 Profit of 521 on sale
2025-06-25SELL-7211.62011.985 11.948USD -860 15.60 Profit of 263 on sale
2025-06-20SELL-14411.49011.880 11.841USD -1,705 15.68 Profit of 554 on sale
2025-05-23BUY729.7209.860 9.846USD 709 16.38
2025-05-19SELL-729.5109.670 9.654USD -695 16.60 Profit of 500 on sale
2025-05-15SELL-2169.4609.670 9.649USD -2,084 16.73 Profit of 1,529 on sale
2025-05-12SELL-7210.18010.380 10.360USD -746 16.91 Profit of 472 on sale
2025-05-09SELL-729.50010.030 9.977USD -718 16.98 Profit of 504 on sale
2025-04-30SELL-7211.53011.720 11.701USD -842 17.42 Profit of 412 on sale
2025-04-24SELL-14411.52011.750 11.727USD -1,689 17.66 Profit of 854 on sale
2025-04-17SELL-7210.24010.265 10.263USD -739 18.02 Profit of 559 on sale
2025-04-15SELL-2169.82010.165 10.130USD -2,188 18.20 Profit of 1,744 on sale
2025-04-14SELL-2169.8509.970 9.958USD -2,151 18.30 Profit of 1,801 on sale
2025-04-09SELL-2889.60010.160 10.104USD -2,910 18.61 Profit of 2,448 on sale
2025-04-07SELL-5049.7209.910 9.891USD -4,985 18.82 Profit of 4,499 on sale
2025-04-04SELL-7209.69010.520 10.437USD -7,515 18.93 Profit of 6,111 on sale
2025-03-31BUY7211.88012.030 12.015USD 865 19.21
2025-03-19SELL-14413.90014.060 14.044USD -2,022 19.88 Profit of 840 on sale
2025-03-14SELL-43213.59013.640 13.635USD -5,890 20.14 Profit of 2,808 on sale
2025-03-13SELL-14613.19014.670 14.522USD -2,120 20.23 Profit of 834 on sale
2025-03-12SELL-2,48214.54014.870 14.837USD -36,825 20.32 Profit of 13,601 on sale
2025-03-07SELL-14613.86014.290 14.247USD -2,080 20.61 Profit of 930 on sale
2025-03-06SELL-21914.05014.430 14.392USD -3,152 20.72 Profit of 1,385 on sale
2025-03-03SELL-7314.19015.510 15.378USD -1,123 21.03 Profit of 412 on sale
2025-02-28SELL-43815.45015.460 15.459USD -6,771 21.12 Profit of 2,479 on sale
2025-02-26SELL-7317.06017.210 17.195USD -1,255 21.29 Profit of 299 on sale
2025-02-25SELL-21916.47016.980 16.929USD -3,707 21.38 Profit of 974 on sale
2025-02-18BUY36516.73018.070 17.936USD 6,547 21.79
2025-02-13BUY7317.57017.850 17.822USD 1,301 22.04
2025-02-12BUY7317.31017.350 17.346USD 1,266 22.14
2025-02-11BUY21917.12018.180 18.074USD 3,958 22.24
2025-02-06BUY65719.04019.530 19.481USD 12,799 22.48
2025-01-27BUY7319.81020.660 20.575USD 1,502 23.14
2024-12-30BUY36518.64019.085 19.040USD 6,950 23.58
2024-12-06BUY29221.37022.080 22.009USD 6,427 23.81
2024-12-05BUY7320.06021.340 21.212USD 1,548 23.94
2024-12-04BUY36520.82021.290 21.243USD 7,754 24.05
2024-11-29BUY36022.11022.230 22.218USD 7,998 24.35
2024-11-27BUY28821.23022.100 22.013USD 6,340 24.62
2024-11-26BUY7221.79022.080 22.051USD 1,588 24.75
2024-11-25SELL-42,32321.82022.790 22.693USD -960,436 24.89 Profit of 93,125 on sale
2024-11-21BUY1,00022.37023.090 23.018USD 23,018 25.18
2024-11-20BUY60022.64022.880 22.856USD 13,714 25.32
2024-11-18BUY2,40021.79022.710 22.618USD 54,283 25.70
2024-11-12BUY1,60027.03028.200 28.083USD 44,933 25.61
2024-11-08BUY1,00027.34027.750 27.709USD 27,709 25.48
2024-11-07BUY3,00027.24028.420 28.302USD 84,906 25.35
2024-11-06BUY40027.00027.275 27.247USD 10,899 25.21
2024-10-31BUY20024.58024.940 24.904USD 4,981 25.37
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NRIX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1976,8690337,08922.8%
2025-09-18115,92697470,43424.6%
2025-09-17126,6710672,96118.8%
2025-09-16103,8500416,87924.9%
2025-09-15262,1910512,07451.2%
2025-09-12144,9620456,36631.8%
2025-09-11113,1840213,49353.0%
2025-09-10110,091853183,50260.0%
2025-09-09136,7630288,47047.4%
2025-09-08123,9465228,58854.2%
2025-09-05123,9370238,53852.0%
2025-09-0472,9400129,91856.1%
2025-09-03181,0680299,30660.5%
2025-09-0276,5100353,68721.6%
2025-08-29203,27842356,57357.0%
2025-08-2855,2460151,08436.6%
2025-08-2771,6173,905118,66060.4%
2025-08-2686,48920165,94752.1%
2025-08-2541,3940100,22041.3%
2025-08-2265,6450165,09339.8%
2025-08-2158,041166177,37732.7%
2025-08-2067,9970191,75435.5%
2025-08-1997,083865296,24032.8%
2025-08-1880,47101,066,5277.5%
2025-08-1559,9120124,04048.3%
2025-08-1479,2250116,84467.8%
2025-08-1397,4330177,94354.8%
2025-08-1273,47477151,97648.3%
2025-08-11103,91753233,58944.5%
2025-08-0885,6990162,58652.7%
2025-08-0770,5880116,88960.4%
2025-08-06215,45841268,13680.4%
2025-08-0578,0950149,09052.4%
2025-08-0470,1414117,12159.9%
2025-08-0199,67485116,92485.2%
2025-07-31218,9450624,75535.0%
2025-07-30162,5854,925194,36783.6%
2025-07-29180,029442376,03447.9%
2025-07-28251,7550464,58554.2%
2025-07-2578,11526128,30660.9%
2025-07-2489,575429240,85737.2%
2025-07-2379,3730288,37827.5%
2025-07-22102,1930188,09354.3%
2025-07-2181,2040127,39163.7%
2025-07-18156,5821,615261,96359.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.